Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for the preparation of an antibacterial preparation for infusion and a method for its preparation (variants)

A composition and drug technology, applied in the directions of drug combinations, antibacterial drugs, antifungal agents, etc., can solve the problems of not enhancing the therapeutic efficacy of antibacterial drugs, being less commonly used, and not having antibacterial effects, and achieving increased efficacy and quality, No waste cost, lower mortality effect

Active Publication Date: 2018-01-12
维克托历沃维奇·利莫诺夫
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] For decades, in the clinical practice of preparing most antibacterial (antibacterial and antifungal) Dextrose (glucose) solution, less commonly 0.45% sodium chloride solution, 2% and 10% dextrose solutions, Ringer's solution, Lactated Ringer's solution, for intravenous infusion Potassium chloride and sodium chloride solutions, etc., these commonly used ingredients do not have antibacterial effects themselves, and have no effect on enhancing the therapeutic efficacy of antibacterial drugs[1]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for the preparation of an antibacterial preparation for infusion and a method for its preparation (variants)
  • Pharmaceutical composition for the preparation of an antibacterial preparation for infusion and a method for its preparation (variants)
  • Pharmaceutical composition for the preparation of an antibacterial preparation for infusion and a method for its preparation (variants)

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0031] Example 1. Preparation of solid composition. NaCl: colloidal silicon dioxide.

[0032] Blends of sodium chloride and colloidal silica in weight ratios of 4.5:1, 4.5:2, 4.5:5, 9:1, 9:2, and 9:5 were processed in a rotary drum mill1 , 2 or 4 hours.

[0033] The particle content of suspensions of initial colloidal silica particles and their composition with NaCl in different variants in water was analyzed on a Microsizer-201а particle size laser analyzer manufactured by the Russian company «VA Instalt». Place 1g to 5g of the powder under study into the sample preparation module (liquid volume 150sm 3 ) in an amount sufficient to transmit 70% to 75% of the light through the test tube. After 1 or 2 minutes, the measurement is taken while the suspension is processed to break up clumps. Data processing is performed according to a calculation program embedded in the analyzer. The results are presented in the form of a histogram of weight distribution versus particle size. ...

example 2

[0040] Example 2. Preparation of solid composition

[0041] Dextrose: Colloidal silicon dioxide. Blends of dextrose and colloidal silica in weight ratios of 20:1, 20:2, 20:5, 50:1, 50:2, and 50:5 were processed in a rotary drum mill1 , 2 or 4 hours.

[0042] Following the method described in Example 1, the particle content of the suspension of colloidal silica in water and the adsorption rate of antibiotics were measured. The data obtained are shown in Table 2. From these data, it can be seen that the method for preparing the provided composition also increases the proportion of the colloidal silica fine powder fraction (particle size ≤ 5 μm) by at least 2 times and the binding of colloidal silica particles to the molecules of the antimicrobial preparation reached at least 40%.

[0043] Table 2

[0044] Particle determination data of suspensions of compositions and solutions of antibacterial preparations in water prepared by application of the composition; adsorption rate...

example 3

[0046] Example 3. Determination of the therapeutic efficacy of a solution (for intravenous injection) based on an antibacterial preparation prepared using a pharmaceutical composition.

[0047] A study has been conducted against β-lactam antibiotics (amoxicillin + clavulanic acid, cefotaxime, ceftriaxone, cefoperazone + sulbactam, ceftazidime, cefepime, aztreonam, meropenem), Research on macrolides (azithromycin), aminoglycosides (amikacin sulfate), glycopeptides (vancomycin), antifungals (voriconazole), and fosfomycin.

[0048] In order to determine the therapeutic efficacy of antimicrobial agents, an experimental model of sepsis was first established, and according to [19, 20], the obtained results (χ 2 ) statistical processing method.

[0049] microorganism : Staphylococcus aureus (ATCC No. 25923F-49), Escherichia coli (ATCC No. 25922F-50), Pseudomonas aeruginosa (ATCC No. 27853F-51), Candida albicans (ATCC No. 24433).

[0050] animal : The experiment was based on "Reg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to pharmacology, medicine, veterinary medicine and the pharmaceutical industry, that is, to pharmaceutical compositions for the preparation of infusion solutions of antibacterial preparations, which are A pharmaceutical composition enhances the therapeutic efficacy of an antibacterial drug; and also relates to a method of preparing an initial compounded pharmaceutical composition. The provided pharmaceutical compositions containing finely divided nanostructured colloidal silica powders for the preparation of injections of all tested antibacterial formulations were tested in the treatment of test animals with Staphylococcus aureus (Staphylococcus aureus), Escherichia coli (Escherichia coli), Pseudomonas aeruginosa (Pseudomonas aeruginosa) and Candida albicans (Candida albicans) caused by refractory sepsis definitely increased its therapeutic efficacy. Compared with traditional solvents (prototype of the present invention), the provided pharmaceutical composition (NaCl: colloidal silicon dioxide and dextrose: colloidal bismuth) for the preparation of antibacterial preparations and antifungal preparations for intravenous infusion Silicon oxide) is clinically of considerable importance in enhancing the therapeutic potential of said antibacterial and antifungal agents for the treatment of malignant infectious and inflammatory diseases.

Description

technical field [0001] The present invention relates to pharmaceutical preparations suitable for the preparation of solutions of injectable preparations of antibacterial drugs and their compounding techniques, which can be used in medicine and veterinary medicine for the treatment of infectious and inflammatory diseases of different etiologies, and in the pharmaceutical industry for the preparation of raw materials drug and final dosage form. Background technique [0002] For decades, in the clinical practice of preparing most antibacterial (antibacterial and antifungal) Dextrose (glucose) solution, less commonly 0.45% sodium chloride solution, 2% and 10% dextrose solutions, Ringer's solution, Lactated Ringer's solution, for intravenous infusion Potassium chloride and sodium chloride solutions, etc., these commonly used ingredients do not have antibacterial effects themselves, and have no effect on enhancing the therapeutic efficacy of antibacterial drugs [1]. [0003] In ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/14A61K47/02A61K47/04A61K47/36A61P31/04A61P31/10
CPCA61K9/10A61K9/143A61K9/145A61K45/00A61K47/02A61K47/26A61K9/0019A61K31/407A61K31/506A61K31/546A61K31/7036A61K31/7052A61K38/14A61K33/14A61P1/04A61P1/10A61P31/00A61P31/04A61P31/10Y02A50/30A61K9/14
Inventor 维克托历沃维奇·利莫诺夫康斯坦丁瓦连京诺维奇·盖杜尔亚历山大瓦莱雷维奇·杜什金
Owner 维克托历沃维奇·利莫诺夫
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com